Conventional v. hypofractionated whole breast radiation therapy

Many Breast Cancer Patients Get Too Much Radiation Therapy, Research Suggests

Jama journal logo
Women need to discuss these options with their radiation oncologist to determine the optimal treatment regimen for their particular case.

New epidemiology study 2008–2013 suggests that many breast cancer U.S. patients still get radiation therapy for much longer than they need to. The analysis of data, involving millions of women, found that two-thirds of breast cancer patients who had breast-conserving surgery (lumpectomy) undergo six to seven weeks of radiation therapy.

The study suggest that hypofractionated whole breast radiation –  newer type of radiation therapy consisting of only three weeks of higher-dose radiation – is just as effective, more convenient, shorter and cheaper than conventional radiation therapy.

Sources and more information
  • Uptake and Costs of Hypofractionated vs Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008–2013, jamanetwork, doi:10.1001/jama.2014.16616, December 10, 2014.
  • Many Breast Cancer Patients Get Too Much Radiation Therapy, Research Suggests, news.health, December 10, 2014.

Liste de 25 médicaments génériques à ne plus utiliser dès maintenant

L’ANSM lance une procédure de suspension, à compter du 18 décembre, de 25 médicaments commercialisés en France

ansm_logo
25 médicaments génériques vont être interdits à la commercialisation par l’ANSM suite à des infractions commises lors des essais cliniques de bioéquivalence. A retirer dès maintenant de votre boite à pharmacie…

Une inspection par l’Agence française du Médicament ANSM d’un site de la société GVK Bio qui réalise des essais cliniques parmi lesquels des essais de bioéquivalence en Inde, a mis en évidence des irrégularités dans des documents associés à ces essais sur lesquels s’appuient les AMM (autorisation de mise sur le marché) de plusieurs médicaments. Même si ces documents ne sont pas indispensables à la démonstration de la bioéquivalence, l’ANSM a décidé, par mesure de précaution, de suspendre les AMM de 25 médicaments génériques commercialisés.

  1. ESCITALOPRAM ABBOTT 10 mg, comprimé pelliculé. ABBOTT PRODUCTS
  2. ESCITALOPRAM ABBOTT 15 mg, comprimé pelliculé. ABBOTT PRODUCTS
  3. ESCITALOPRAM ABBOTT 20 mg, comprimé pelliculé .ABBOTT PRODUCTS
  4. ESCITALOPRAM ABBOTT 5 mg, comprimé pelliculé. ABBOTT PRODUCTS
  5. EBASTINE BIOGARAN 10 mg, comprimé orodispersible. BIOGARAN
  6. DESLORATADINE CRISTERS 5 mg, comprimé pelliculé. CRISTERS
  7. IBUPROFENE CRISTERS 400 mg, comprimé pelliculé. CRISTERS
  8. DESLORATADINE ARROW 5 mg, comprimé pelliculé .LABORATOIRES GERDA
  9. DESLORATADINE GNR 5 mg, comprimé pelliculé. MEDIPHA SANTE
  10. CANDESARTAN MYLAN 32 mg, comprimé. MYLAN SAS
  11. DONEPEZIL MYLAN 10 mg, comprimé orodispersible. MYLAN SAS
  12. DONEPEZIL MYLAN 5 mg, comprimé orodispersible. MYLAN SAS
  13. EBASTINE MYLAN 10 mg, comprimé orodispersible. MYLAN SAS
  14. RIZATRIPTAN MYLAN 10 mg, comprimé orodispersible .MYLAN SAS
  15. TRIMETAZIDINE MYLAN 35 mg, comprimé à libération modifiée . MYLAN SAS
  16. DESLORATADINE TEVA SANTE 5 mg, comprimé pelliculé. TEVA SANTE
  17. DESLORATADINE ZYDUS 5 mg, comprimé pelliculé. ZYDUS France
  18. ESCITALOPRAM ZYDUS 10 mg, comprimé pelliculé. ZYDUS France
  19. ESCITALOPRAM ZYDUS 15 mg, comprimé pelliculé. ZYDUS France
  20. ESCITALOPRAM ZYDUS 20 mg, comprimé pelliculé. ZYDUS France
  21. ESCITALOPRAM ZYDUS 5 mg, comprimé pelliculé. ZYDUS France
  22. IBUPROFENE ZF 400 mg, comprimé pelliculé. ZYDUS France
  23. IBUPROFENE ZYDUS FRANCE 200 mg, comprimé pelliculé. ZYDUS France
  24. IBUPROFENE ZYDUS FRANCE 400 mg, comprimé pelliculé. ZYDUS France
  25. TRAMADOL PARACETAMOL ZYDUS FRANCE 37,5 mg/325 mg comprimé pelliculé. ZYDUS France

Cette décision est prise à titre de précaution. Aucun élément n’a, à ce jour, conduit a établir un risque avéré pour la santé humaine ou un manque d’efficacité de ces médicaments. Ces suspensions ne touchent que certaines spécialités des marques concernées par ces irrégularités. Il n’y a pas de risque d’interruption de traitement dans la mesure où ces médicaments sont disponibles sous d’autres marques.

Les autorités européennes ont été saisies par la France et, dans l’attente de leur décision finale, l’Allemagne, la Belgique et le Luxembourg ont également décidé de suspendre les AMM des médicaments concernés.

Sources et plus d’informations

L’ANSM lance une procédure de suspension, à compter du 18 décembre, de 25 médicaments commercialisés en France – Point d’Information,
ANSM Actualité, 05/12/2014.
Alerte Santé : 25 médicaments génériques à ne plus consommer,
bioaddict, 09/12/2014.

Say NO to hormone disrupting chemicals!

TELL THE EUROPEAN COMMISSION THAT YOU WANT TO REMOVE HORMONE DISRUPTING CHEMICALS FROM OUR LIVES TO PROTECT OUR HEALTH!

Say NO to hormone disrupting chemicals banner
Tell the @EU_Commission to find & remove all #HormoneDisruptingChemicals from our lives to protect our #health!

Due to intensive industry lobbying, the European Commission has delayed action on hormone disrupting chemicals, which is needed to protect health. But now a public consultation has been launched to gather feedback on public concerns. We need you to help us!

As the European Commission has made this public consultation very technical, the EDC-Free Europe coalition has launched an easy to use online platform to enable individuals to submit prepared answers to the European Commission.

This is the only chance you will have to directly give your opinion and call for the urgent removal of hormone-disrupting chemicals from our lives to protect our health!

It will take you less than five minutes to take action. Just fill in your details and with the help of four simple steps your submission will be sent directly to the European Commission. Take action at the No2HormoneDisruptingChemicals.org website.

Need a reminder why we need action?

Watch the video Endocrination – The Magnitude of the Endocrine Disruptors Issue. An amusing film by French journalist Stephane Horel exposes the battle created by industry lobbying on hormone disrupting chemicals.

Why do we need to act urgently now?

Our everyday exposure to hormone disrupting chemicals – in our food, cosmetics, electronic products, schools, hospitals and workplaces, to name a few, must stop in order to protect the health of current and future generations. Humans and wildlife are vulnerable to exposure to these chemicals every day, which are very likely to be contributing to the dramatic increases in many serious, life threatening diseases and health disorders.

By responding to the public consultation, you are sending a strong signal to the European Commission that there are serious concerns and public support for action to protect us, the environment and our children in Europe and beyond. Take action now and say NO2HormoneDisruptingChemicals.

Video de l’étude 2013 DES 3 générations: filles DES et risque de cancers

Le risque de cancer du sein apparaît multiplié par deux

Interview du Pr Michel Tournaire – du comité scientifique de l’étude Réseau DES France Distilbène 3 Générations de 2013 – par Laeticia Dormoy, administratrice de Réseau DES France.
Le Pr Tournaire – qui avait présenté l’étude en nov. 2013 – parle des filles DES et risque de cancers ; le risque de cancer du sein apparaît multiplié par deux.
Vidéo publiée le 1.12.2014 par Réseau DES FRANCE DISTILBENE.

Les résultats publiés

Le Distilbène DES, en savoir plus

Livestock: Climate Change’s forgotten Sector

Eating less meat essential to curb climate change

chattam house pdf cover image
Dietary change is essential if global warming is not to exceed 2C, says report

Global livestock industry produces more greenhouse gas emissions than transport but fear of a consumer backlash is preventing action, says Chatham House report.

Summary

Consumption of meat and dairy produce is a major driver of climate change.
  • Greenhouse gas emissions from the livestock sector are estimated to account for 14.5 per cent of the global total, more than direct emissions from the transport sector.
  • Even with ambitious supply-side action to reduce the emissions intensity of livestock production, rising global demand for meat and dairy produce means emissions will continue to rise.
Shifting global demand for meat and dairy produce is central to achieving climate goals.
  • Recent analyses have shown that it is unlikely global temperature rises can be kept below two degrees Celsius without a shift in global meat and dairy consumption.
  • Reducing demand for animal products could also significantly reduce mitigation costs in nonagricultural sectors by increasing their available carbon budget.
However, there is a striking paucity of efforts to reduce consumption of meat and dairy products.
  • A number of factors, not least fear of backlash, have made governments and environmental groups reluctant to pursue policies or campaigns to shift consumer behaviour.
  • The lack of attention afforded to the issue among policy-makers and opinion-formers contributes to a lack of research on how best to reduce meat and dairy consumption.
  • As a first step in addressing this lack of research, Ipsos MORI was commissioned by Chatham House to undertake the first multi-country, multilingual online survey specifically to explore public attitudes on the relationship between meat/dairy consumption and climate change.
The data presented in this paper reveal a major awareness gap about livestock’s
contribution to climate change.
  • Compared with other sectors, recognition of the livestock sector as a significant contributor to climate change is markedly low.
  • Consumers with a higher level of awareness were more likely to indicate willingness to reduce their meat and dairy consumption for climate objectives. Closing the awareness gap is therefore likely to be an important precondition for behaviour change.
  • Those actors most trusted to inform consumers on the links between livestock and climate change are generally ‘experts’ and environmental groups, though important differences exist between countries.
Climate change is not currently a primary consideration in food choices.
  • Climate change is generally secondary to immediate considerations of taste, price, health and food safety in shaping food choices.
  • This has important implications for the design of strategies to moderate meat and dairy consumption: those that emphasize co-benefits (e.g. for health and expenditure) and do not require consumers to compromise on enjoyment are likely to be more successful.
Some of the greatest potential for behaviour change appears to lie in emerging economies.
  • Respondents to the online survey in Brazil, China and India demonstrated high levels of acceptance of anthropogenic climate change, greater consideration of climate change when choosing meat and dairy, and a greater willingness to modify their consumption behaviour than the average of the countries assessed.
  • This is encouraging as these countries are among the most important for future demand for meat and dairy products.

Sources and more information

  • Full PDF by Chathamhouse Research Paper, Global Public Opinion on Meat and Dairy Consumptionfield_document, December 2014.
  • Eating less meat essential to curb climate change, says report, the guardian, 3 December 2014.
  • Let’s talk about meat, eating-better, December 2014.

Consuming canned beverage increase BPA exposure, blood pressure and risk of heart disease

Exposure to Bisphenol A From Drinking Canned Beverage Increases Blood Pressure

coke can image
People with high blood pressure or heart disease, should be aware of the possible risks from increased blood pressure when consuming canned beverages or foods.

Researchers from Seoul National University, South Korea, found that drinking from cans – many of which have linings that contain the chemical bisphenol A (BPA) – can raise blood pressure by 16 times compared to drinking from glass bottles.

Because hypertension is a well-known risk factor for heart disease, this study showing the link of BPA exposure to elevation in blood pressure strongly suggests that BPA exposure may increase the risk of heart disease

Sources and more information
  • Exposure to Bisphenol A From Drinking Canned Beverage Increases Blood Pressure, AHA Journals, doi: 10.1161/HYPERTENSIONAHA.114.04261, December 8, 2014.
  • The Other Reason Canned Food Is Raising Your Blood Pressure, Time, 8 Dec 2014.
  • BPA in Canned Goods May Raise Your Blood Pressure: Study, HealthDay, 8 Dec 2014.

VitaminE Deficiency linked to increased Risk of Miscarriage

Maternal vitamin E status in the first trimester may influence risk of early pregnancy loss

JHU Public Health logo
Team @JohnsHopkinsSPH found that maternal vitamin E status in the first trimester may influence risk of early pregnancy loss.

Vitamin E is found in a variety of foods. It is required for the proper function of many organs in the body. It works as an antioxidant, which means it helps to slow down processes that damage cells.

Researchers from Johns Hopkins Bloomberg School of Public Health found that pregnant women in Bangladesh with low levels of the most common form of vitamin E are nearly twice as likely to have a miscarriage than those with adequate levels of the vitamin in their blood.

Sources and more information

  • Vitamin E Deficiency Linked to Greater Risk of Miscarriage Among Poor Women, jhsph news, December 3, 2014.
  • First trimester plasma tocopherols are associated with risk of miscarriage in rural Bangladesh, ajcn nutrition, November 26, 2014.

Get Your Antibiotic Guardian Certificate

Did you pledge to be an Antibiotic Guardian?
Choose one simple pledge and get your certificate!

Antibiotic Guardian Certificate image
Watch @DES_Journal health posters album on Flickr.

Do you know that antibiotic resistance continues to rise due to increase in use in the UK? Did you pledge to be an #AntibioticGuardian for #EAAD2014? Not yet? Visit antibioticguardian.com and choose one simple pledge about how you’ll make better use of antibiotics and help save this vital medicine from becoming obsolete.

On Flickr®

Sharp rise in the misuse of antibiotic ceftiofur in livestock poses a threat to public health

Ceftiofur, wonder drug for dairy farmers, endangers public health

mdf267299
The antibiotic ceftiofur is a wonder drug for dairy farmers. But its strength – and the frequency at which it’s used improperly in cattle – pose a threat to public health.

It is one of the most potent antibiotics used by U.S. cattle and dairy farmers, the key component in the top-selling drug line of Zoetis, the world’s largest animal health company. But the strength of the antibiotic ceftiofur – and the frequency with which it’s being misused on farms across America – has created a threat to human health that may overshadow the drug’s effectiveness, a Reuters examination shows

The U.S. Food and Drug Administration cautioned in 2012 that ceftiofur could pose a “high public health risk,” in part because the drug belongs to a class of antibiotics considered critically important in human medicine. The warning is the FDA’s strongest kind. The concern is that ceftiofur in animals could spawn antibiotic-resistant bacteria, superbugs that can infect people and defeat conventional medical treatment, even when the drug is used as directed. ”

continue reading Reuters Investigation Farmaceuticals, The drugs fed to farm animals and the risks posed to humans, includes:

  • The antibiotic ceftiofur is a wonder drug for dairy farmers. But its strength – and the frequency at which it’s used improperly in cattle – pose a threat to public health
  • Floored by a superbug
More press releases
  • Abusing Chickens We Eat,
    nytimes, Nicholas D. Kristof, DEC. 3, 2014
  • Watch What It’s Like to Be a Factory-Farmed Chicken,
    motherjones, Dec. 4, 2014.
  • Perdue Whistleblower Video Reveals Horrors,
    opednews, Martha Rosenberg, Dec. 4, 2014.
  • Hoping to Change the Industry, a Factory Farmer Opens His Barn Doors, wired, Dec. 4, 2014.
  • Better Chicken Initiative, CWIF.

Video de l’étude 2013 DES 3 générations: contexte et organisation

Lancement, contenu, nombre de personnes impliquées

Interview du Pr Michel Tournaire – du comité scientifique de l’étude Réseau DES France Distilbène 3 Générations de 2013 – par Laeticia Dormoy, administratrice de Réseau DES France.
Le Pr Tournaire – qui avait présenté l’étude en nov. 2013 – explique pourquoi cette étude a eu lieu, comment elle a été organisée, les sujets traités et le nombre de personnes impliquées.
Vidéo publiée le 1.12.2014 par Réseau DES FRANCE DISTILBENE.

Les résultats publiés

Le Distilbène DES, en savoir plus